title: A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study.
abstract: Prior longitudinal observational studies have examined the practice patterns and outcomes of anaemia management, including the use of erythropoiesis-stimulating agents (ESAs). Several dimensions of effectiveness remain unaddressed; especially considering the revised ESA label (target Hb levels between 10 and 12 g/dL), the recently published TREAT study, and the European approval of the first ESA biosimilar (HX575). Anecdotal evidence suggests that patient outcomes are influenced by physician-related variables and whether anaemia management is congruent with practice guidelines, but this has not been studied systematically. MONITOR-CKD5 is an international, prospective, observational, pharmacoepidemiological study evaluating the multi-level factors and outcomes of treatment with HX575 for renal anaemia in haemodialysis patients. Driven by a novel, integrated, multi-focal framework for post-approval observational studies, it examines determinants of response at both the patient and the physician level; integrates an advocated statistical methodology here to fore used mainly in the social and behavioural sciences; assesses factors potentially predictive of a poor treatment response; and evaluates the extent to which treatment is congruent with evidence-based guidelines, good practice evidence, and the revised ESA label. This pan-European study will recruit at least 1,000 patients from a minimum of 75 centres, and follow them for up to 24 months following initiation of anaemia management with biosimilar epoetin alfa. MONITOR-CKD5 will not only study the core issues addressed by prior observational studies but also aims to take knowledge discovery a step further by assessing outcomes across varying cohorts of patients, and examining the impact of evidence-based practice on clinical outcomes, differentiating, in the process, between physician-level and patient-level determinants.
authors: Department of Nephrology, Università degli Studi di Bari, Bari, Italy. l.gesualdo@unifg.it
authors: Loreto
authors: L
authors: Gesualdo
authors: Gérard
authors: G
authors: London
authors: Matthew
authors: M
authors: Turner
authors: Christopher
authors: C
authors: Lee
authors: Karen
authors: K
authors: Macdonald
authors: David
authors: D
authors: Goldsmith
authors: Adrian
authors: A
authors: Covic
authors: Philippe
authors: P
authors: Zaoui
authors: Christian
authors: C
authors: Combe
authors: Johannes
authors: J
authors: Mann
authors: Frank
authors: F
authors: Dellanna
authors: Michael
authors: M
authors: Muenzberg
authors: Ivo
authors: I
authors: Abraham
references: Nephrol Dial Transplant. 2010 Jun;25(6):1734-7
references: 20200007
references: Clin Nephrol. 2009 Nov;72(5):380-90
references: 19863881
references: Blood Purif. 2004;22(1):175-80
references: 14732826
references: Int J Clin Pharmacol Ther. 2009 Jun;47(6):391-401
references: 19473601
references: Am J Kidney Dis. 2006 Jan;47(1):24-36
references: 16377382
references: Arch Intern Med. 2002 Jun 24;162(12):1401-8
references: 12076240
references: Nephrol Dial Transplant. 2004 Jan;19(1):121-32
references: 14671047
references: Lancet. 2005 May 7-13;365(9471):1657-61
references: 15885299
references: Clin Nephrol. 2000 Feb;53(1 Suppl):S2-8
references: 10746799
references: Nephrol Dial Transplant. 2009 Feb;24(2):348-54
references: 19037082
references: Eur J Clin Invest. 2005 Dec;35 Suppl 3:58-65
references: 16281960
references: Nephrol Dial Transplant. 2005 May;20 Suppl 3:iii25-32
references: 15824127
references: Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
references: 11904577
references: Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003967
references: 17054191
references: Nephrol Dial Transplant. 2005 May;20 Suppl 3:iii3-24
references: 15824128
references: Nephrol Dial Transplant. 2004 Jan;19(1):108-20
references: 14671046
references: Nephrol Dial Transplant. 2004 May;19 Suppl 2:ii1-47
references: 15206425
references: Nephrol Dial Transplant. 2000;15 Suppl 4:15-9
references: 11052145
references: BMC Clin Pharmacol. 2009 May 22;9:10
references: 19463151
references: Kidney Int. 2005 Oct;68(4):1432-8
references: 16164618
references: Am J Kidney Dis. 2004 Jul;44(1):94-111
references: 15211443
references: Kidney Int. 2008 Nov;74(10):1237-40
references: 18596731
references: Nephrol Dial Transplant. 2005 May;20(5):927-35
references: 15728270
references: Health Aff (Millwood). 2005 Jan-Feb;24(1):18-28
references: 15647212
references: Clin J Am Soc Nephrol. 2008 Jan;3(1):133-8
references: 18045862
references: Am J Nephrol. 2008;28(5):792-801
references: 18477842
references: Clin J Am Soc Nephrol. 2006 Mar;1(2):246-55
references: 17699213
references: J Am Soc Nephrol. 2010 Jan;21(1):2-6
references: 20035034
references: N Engl J Med. 2009 Nov 19;361(21):2019-32
references: 19880844
references: Am J Kidney Dis. 2007 Sep;50(3):471-530
references: 17720528
references: Biometrics. 1987 Mar;43(1):213-23
references: 3567306